

file  
CDP aspirin  
115

May 22, 1975

Curtis L. Meinert, Ph.D.  
CDP Coordinating Center  
University of Maryland  
Department of Preventive Medicine  
Division of Clinical Investigation  
610 West Lombard Street  
Baltimore, MD 21201

Dear Curt,

I'm sorry my Visiting Scientist stint in Baltimore involved missing you in Chicago and Baltimore.

The aspirin paper is superb. I would like to suggest two small, but I think significant changes in wording in this and other CDP papers.

One Qn, we cause trouble for ourselves and for science by using "proof" and the expression on page 15, line 4 that results "suggest ... but do not prove...", etc. "Proof" is a weaker word than it would seem, inferences of cause and proof do not necessarily require trials or experiment. Trials and experiment do not necessarily imply proof. Philosophy, but important.

Second, I feel that our general statement about aspirin (or niacin and clofibrate for that matter) as possibly effective in coronary heart disease might better be expressed as being in myocardial infarct survivors. I've heard others criticize our CDP conclusions as being too general.

Cordially,

Henry Blackburn, M.D.

HB:jp

hpc  
Blackburn